Scarica l'app Stockscreener
14.31
0.14%
-0.02
Dopo l'orario di chiusura:
14.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Why Amicus Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Final Week & Trade Opportunity Analysis - mfd.ru
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Amicus Therapeutics (FOLD) to Release Earnings on Wednesday - MarketBeat
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics (FOLD) Stock Analysis: Navigating Growth In Rare Disease Biotech - DirectorsTalk Interviews
Metabolism Drugs Market Booming with Rapid Growth Through 2033 | - openPR.com
New York State Common Retirement Fund Raises Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments - Yahoo Finance
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Amicus to present new data on rare disease treatments at symposium - Investing.com Canada
Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential - DirectorsTalk Interviews
Amicus (FOLD) Shares New Data at WORLDSymposium 2026 - GuruFocus
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - The Manila Times
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
BioMarin-Amicus file US antitrust paperwork, make EU referral request - MLex
BioMarin-Amicus US antitrust deadline set to expire on Feb. 20; EU referral sought - MLex
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain? - simplywall.st
Y Intercept Hong Kong Ltd Sells 723,540 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - Sahm
BioMarin’s Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach - Yahoo Finance
Fundamentals Check: Does BLKB meet Warren Buffetts criteriaTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Will Amicus Therapeutics Inc. benefit from AI trends2025 Geopolitical Influence & Fast Moving Stock Watchlists - mfd.ru
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by Zacks Research - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Upside with Strategic Growth in Rare Disease Therapeutics - DirectorsTalk Interviews
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Market Recap: What is the long term forecast for Amicus Therapeutics Inc stockMarket Growth Report & Weekly High Momentum Picks - baoquankhu1.vn
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - marketscreener.com
Amicus Therapeutics CEO Campbell sells $1.07 million in shares By Investing.com - Investing.com Canada
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Sells 75,000 Shares - TradingView
How the $4.8B Amicus deal with BioMarin came together - The Business Journals
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Amicus Therapeutics (FOLD): Jefferies Downgrades to Hold, Lowers Price Target | FOLD Stock News - GuruFocus
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook - Investing.com Canada
How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story - Yahoo Finance
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease - Yahoo Finance
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Yahoo Finance
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com - Investing.com Nigeria
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):